US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
WO1990006952A1
(en)
*
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
IL112583A0
(en)
*
|
1994-02-08 |
1995-05-26 |
Amgen Inc |
Oral delivery of chemically modified proteins
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
WO1996041813A2
(en)
*
|
1994-11-09 |
1996-12-27 |
Offord Robin E |
Functionalized polymers for site-specific attachment
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
ES2214551T3
(es)
|
1995-11-02 |
2004-09-16 |
Schering Corporation |
Terapia de infusion continua de citocinas a baja dosis.
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
CA2273852C
(en)
|
1996-12-06 |
2009-09-29 |
Amgen Inc. |
Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
|
ATE200030T1
(de)
*
|
1997-01-29 |
2001-04-15 |
Polymasc Pharmaceuticals Plc |
Pegylationsverfahren
|
HUP0001153A3
(en)
|
1997-06-06 |
2000-12-28 |
Kyowa Hakko Kogyo Kk |
Chemically modified polypeptides, process for producing thereof, pharmaceutical compositions comprising these polypeptides and their use
|
CN1269805A
(zh)
*
|
1997-07-14 |
2000-10-11 |
博尔德生物技术公司 |
生长激素和相关蛋白的衍生物
|
US20080076706A1
(en)
*
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
IL139286A
(en)
*
|
1998-04-28 |
2005-12-18 |
Applied Research Systems |
Polyol-ifn-beta conjugates, their preparation and use
|
DE69901321T2
(de)
*
|
1998-05-15 |
2002-12-12 |
Schering Corp., Kenilworth |
Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
|
NL1009601C2
(nl)
*
|
1998-07-09 |
2000-01-11 |
Univ Utrecht |
Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze.
|
JP2002520040A
(ja)
*
|
1998-07-16 |
2002-07-09 |
ハイセック,インコーポレーテッド |
新規cd39様ポリペプチドに関する方法および材料
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
DK1588716T3
(da)
*
|
1998-08-06 |
2011-05-23 |
Mountain View Pharmaceuticals |
Peg-uratoxidase-konjugater og anvendelse deraf
|
US6420339B1
(en)
*
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
PT1121156E
(pt)
*
|
1998-10-16 |
2006-05-31 |
Biogen Idec Inc |
Conjugados de polimeros de interferao-beta-1a e as suas utilizacoes
|
DE69931507T2
(de)
*
|
1998-10-16 |
2007-01-11 |
Biogen Idec Ma Inc., Cambridge |
Interferon-beta fusionsproteine und deren verwendungen
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
KR100719202B1
(ko)
*
|
1998-10-23 |
2007-05-16 |
키린-암젠 인코포레이티드 |
MPl 수용체에 결합하는 화합물 및 이를 함유하는 제약학적 조성물
|
EP1135493A2
(en)
*
|
1998-11-30 |
2001-09-26 |
Eli Lilly And Company |
Erythropoietic compounds
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
NZ513077A
(en)
|
1999-01-14 |
2004-03-26 |
Bolder Biotechnology Inc |
Methods for making proteins containing free cysteine residues
|
DK1157037T3
(da)
*
|
1999-01-29 |
2003-11-24 |
Hoffmann La Roche |
GCSF-konjugater
|
EP1369429A1
(en)
*
|
1999-01-29 |
2003-12-10 |
F. Hoffmann-La Roche Ag |
GCSF conjugates
|
WO2000051626A1
(fr)
*
|
1999-03-01 |
2000-09-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Preparations de g-csf modifiees chimiquement
|
US6485718B1
(en)
|
1999-04-13 |
2002-11-26 |
Pharmacia Corporation |
Site specific ligation of proteins to synthetic particles
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US7074878B1
(en)
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
MXPA02006795A
(es)
|
2000-01-10 |
2005-04-19 |
Maxygen Holdings Ltd |
Conjugados g-csf.
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
JP2003521930A
(ja)
|
2000-02-11 |
2003-07-22 |
マキシゲン・エイピーエス |
第VII因子または第VIIa因子様分子
|
US7049761B2
(en)
*
|
2000-02-11 |
2006-05-23 |
Altair Engineering, Inc. |
Light tube and power supply circuit
|
ES2220673T3
(es)
|
2000-02-29 |
2004-12-16 |
Pfizer Products Inc. |
Factor estimulante de colonias de granulocitos estabilizado.
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
WO2001076639A2
(en)
*
|
2000-04-06 |
2001-10-18 |
Pharmacia Corporation |
Chemically-modified myelopoietin conjugates
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
CA2406390A1
(en)
*
|
2000-04-14 |
2001-10-25 |
University Of South Carolina Research Foundation |
Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
|
CA2407083A1
(en)
|
2000-04-21 |
2001-11-01 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
EP1299415A4
(en)
*
|
2000-07-12 |
2005-01-19 |
Gryphon Therapeutics Inc |
MODULATOR OF THE CHEMOKINE RECEPTOR, PRODUCTION AND USE THEREOF
|
YU17603A
(sh)
*
|
2000-09-08 |
2006-05-25 |
Gryphon Sciences |
Sintetički proteini koji stimulišu eritropoezu
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
WO2002026265A2
(en)
*
|
2000-09-29 |
2002-04-04 |
Schering Corporation |
Pegylated interleukin-10
|
ATE421535T1
(de)
*
|
2000-10-16 |
2009-02-15 |
Chugai Pharmaceutical Co Ltd |
Peg-modifiziertes erythropoietin
|
EP1353701B1
(en)
*
|
2000-10-31 |
2011-12-21 |
PR Pharmaceuticals, Inc. |
Methods for producing compositions for enhanced delivery of bioactive molecules
|
EP1334127A1
(en)
*
|
2000-11-02 |
2003-08-13 |
Maxygen Aps |
Single-chain multimeric polypeptides
|
CN1321134C
(zh)
*
|
2000-11-23 |
2007-06-13 |
赵剑 |
一种生物活性蛋白质的非均一制品及其制备方法
|
BR0116206A
(pt)
*
|
2000-12-14 |
2003-12-23 |
Amylin Pharmaceuticals Inc |
Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
|
US7053150B2
(en)
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
TW593427B
(en)
*
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
CA2431964C
(en)
*
|
2000-12-20 |
2013-09-10 |
F. Hoffmann-La Roche Ag |
Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
|
US7442370B2
(en)
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
EP1392731B1
(en)
*
|
2001-02-06 |
2008-07-02 |
Merk Patent Gmbh |
Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
|
EP1234583A1
(en)
*
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-conjugates of HGF-NK4
|
ATE432288T1
(de)
|
2001-02-27 |
2009-06-15 |
Maxygen Aps |
Neue interferon-beta-ähnliche moleküle
|
US7276580B2
(en)
|
2001-03-12 |
2007-10-02 |
Biogen Idec Ma Inc. |
Neurotrophic factors
|
US7247618B2
(en)
*
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
JP2004535388A
(ja)
*
|
2001-04-30 |
2004-11-25 |
ターゲティッド ジェネティクス コーポレイション |
脂質含有薬物送達複合体およびそれらの生成方法
|
NZ529267A
(en)
|
2001-05-11 |
2006-05-26 |
Amgen Inc |
Peptides and related molecules that bind to tall-1
|
DK1421175T3
(da)
*
|
2001-06-28 |
2009-03-23 |
Mountain View Pharmaceuticals |
Polymerstabiliserede proteinaser
|
EP1425304B9
(en)
*
|
2001-07-11 |
2010-09-08 |
Maxygen, Inc. |
G-csf conjugates
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
EP1450838A4
(en)
*
|
2001-10-05 |
2005-09-28 |
Intermune Inc |
METHOD FOR THE TREATMENT OF HEPATITIS INFECTIONS WITH A MULTIPHASIC INTERFERON DELIVERY PROFILE
|
US6908963B2
(en)
*
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
SI1436012T1
(en)
|
2001-10-18 |
2018-03-30 |
Nektar Therapeutics |
Polymer conjugates of opioid antagonists
|
CN100484569C
(zh)
*
|
2001-11-19 |
2009-05-06 |
协和发酵工业株式会社 |
将多潜能干细胞从组织中流通到外周血的药物
|
IL162031A0
(en)
*
|
2001-11-20 |
2005-11-20 |
Pharmacia Corp |
Chemically-modified human growth hormone conjugates
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
KR100480432B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
G-csf와 폴리에틸렌글리콜 유도체의 배합체
|
WO2003049760A1
(en)
*
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
AU2003209227A1
(en)
|
2002-01-14 |
2003-07-30 |
The General Hospital Corporation |
Biodegradable polyketal polymers and methods for their formation and use
|
PL397261A1
(pl)
|
2002-01-18 |
2012-03-26 |
Biogen Idec Ma Inc. |
Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20030199464A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Silviu Itescu |
Regeneration of endogenous myocardial tissue by induction of neovascularization
|
EP1549336B1
(en)
*
|
2002-06-14 |
2011-01-05 |
Amylin Pharmaceuticals, Inc. |
Prevention and/or treatment of ulcerative colitis using pyy or pyy[3-36]
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
AU2003256613A1
(en)
*
|
2002-07-19 |
2004-02-09 |
Amgen Inc. |
Protein conjugates with a water-soluble biocompatible, biogradable polymer
|
WO2004009082A1
(en)
*
|
2002-07-19 |
2004-01-29 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
EP1545578A4
(en)
|
2002-08-28 |
2010-07-07 |
Immunex Corp |
COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
|
CA2498167C
(en)
|
2002-09-09 |
2012-03-20 |
Nektar Therapeutics Al, Corporation |
Water-soluble polymer alkanals
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
JP2004196770A
(ja)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
樹状細胞前駆体の血中レベル上昇剤
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
US20040136952A1
(en)
|
2002-12-26 |
2004-07-15 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
KR101238517B1
(ko)
*
|
2002-12-26 |
2013-02-28 |
마운틴 뷰 파마슈티컬즈, 인크. |
생물학적 효능이 향상된 인터페론-베타의 중합체 접합체
|
EP1577323B1
(en)
|
2002-12-26 |
2013-07-10 |
Takeda Pharmaceutical Company Limited |
Metastin derivative and use thereof
|
WO2004061094A1
(en)
|
2002-12-30 |
2004-07-22 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
US7803362B2
(en)
*
|
2003-01-24 |
2010-09-28 |
Synageva Biopharma Corp. |
Glycosylated interferon alpha
|
JP2006519235A
(ja)
*
|
2003-02-26 |
2006-08-24 |
インターミューン インコーポレイティッド |
ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
|
WO2004078127A2
(en)
*
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Continuous delivery methods for treating hepatitis virus infection
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
NZ542873A
(en)
|
2003-03-05 |
2008-07-31 |
Halozyme Inc |
Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
CN102212019B
(zh)
|
2003-03-14 |
2015-05-27 |
蔚所番有限公司 |
支化水溶性聚合物及其缀合物
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
BRPI0408946A
(pt)
*
|
2003-03-28 |
2006-04-04 |
Biopolymed Inc |
material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo
|
CA2520875A1
(en)
|
2003-03-31 |
2004-10-21 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
CA2522345A1
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
BR122016021907B8
(pt)
|
2003-04-11 |
2021-07-27 |
Antriabio Inc |
conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso
|
DE602004025799D1
(de)
|
2003-04-15 |
2010-04-15 |
Glaxosmithkline Llc |
Humane il-18 substitutionsmutanten und deren konjugate
|
CA2864810A1
(en)
|
2003-04-18 |
2004-11-04 |
Biogen Idec Ma, Inc. |
Polymer-conjugated glycosylated neublastin
|
EP2390262A1
(en)
|
2003-05-16 |
2011-11-30 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
MXPA06001000A
(es)
*
|
2003-07-22 |
2006-05-15 |
Nektar Therapeutics Al Corp |
Metodo para preparar polimeros funcionalizados a partir de alcoholes polimericos.
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
US7267960B2
(en)
|
2003-07-25 |
2007-09-11 |
Amgen Inc. |
Antagonists and agonists of LDCAM and methods of use
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
US7691975B2
(en)
*
|
2003-08-25 |
2010-04-06 |
Toray Industries, Inc. |
Interferon-β complex
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
WO2005028539A2
(en)
|
2003-09-17 |
2005-03-31 |
Nektar Therapeutics Al, Corporation |
Multi-arm polymer prodrugs
|
BRPI0414571A
(pt)
*
|
2003-09-22 |
2006-11-07 |
Boehringer Ingelheim Int |
peptìdeos macrocìclicos ativos contra o vìrus da hepatite c
|
WO2005035727A2
(en)
*
|
2003-10-09 |
2005-04-21 |
Ambrx, Inc. |
Polymer derivatives
|
CA2542179A1
(en)
|
2003-10-10 |
2005-04-21 |
Novo Nordisk A/S |
Il-21 derivatives
|
EP1675871A2
(en)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
TWI375679B
(en)
|
2003-10-14 |
2012-11-01 |
Hoffmann La Roche |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
EP1725572B1
(de)
|
2003-11-05 |
2017-05-31 |
AGCT GmbH |
Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
WO2005053730A1
(ja)
*
|
2003-12-05 |
2005-06-16 |
Kirin Beer Kabushiki Kaisha |
末期心不全治療剤
|
WO2005067963A1
(en)
*
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
NZ548123A
(en)
|
2004-01-08 |
2010-05-28 |
Novo Nordisk As |
O-linked glycosylation of peptides
|
EP1730167B1
(en)
*
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Macrocyclic peptides active against the hepatitis c virus
|
NZ548255A
(en)
|
2004-02-02 |
2010-10-29 |
Ambrx Inc |
Modified human interferon polypeptides and their uses
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
EP1789440A4
(en)
|
2004-02-11 |
2008-03-12 |
Amylin Pharmaceuticals Inc |
REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
|
JP2007525495A
(ja)
|
2004-02-11 |
2007-09-06 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
選択可能な特性を有するハイブリッドポリペプチド
|
EP1734988A4
(en)
*
|
2004-03-01 |
2009-08-05 |
Enzon Pharmaceuticals Inc |
INTERFERON BETA-polymer
|
AU2005229001A1
(en)
*
|
2004-03-23 |
2005-10-13 |
Amgen Inc. |
Chemically modified protein compositions and methods
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
TW200611910A
(en)
|
2004-05-19 |
2006-04-16 |
Maxygen Inc |
Interferon-alpha polypeptides and conjugates
|
WO2005123113A2
(en)
*
|
2004-06-14 |
2005-12-29 |
Intermune, Inc. |
Interferon compositions and methods of use thereof
|
EP1771205B1
(en)
|
2004-06-18 |
2016-10-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
NZ552029A
(en)
|
2004-06-25 |
2009-01-31 |
Takeda Pharmaceutical |
Metastin derivatives and use thereof
|
CA2572751A1
(en)
*
|
2004-06-30 |
2006-01-12 |
Egen Corporation |
Pegylated interferon alpha-1b
|
US8143380B2
(en)
*
|
2004-07-08 |
2012-03-27 |
Amgen Inc. |
Therapeutic peptides
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
KR20070039593A
(ko)
|
2004-07-21 |
2007-04-12 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
EP2238983B1
(en)
|
2004-08-19 |
2014-07-23 |
Biogen Idec MA Inc. |
Neublastin variants
|
JP4959566B2
(ja)
|
2004-08-19 |
2012-06-27 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
トランスホーミング増殖因子βファミリータンパク質の折りたたみ
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
ES2529451T3
(es)
|
2004-09-23 |
2015-02-20 |
Vasgene Therapeutics, Inc. |
Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
|
EP3061461A1
(en)
|
2004-10-29 |
2016-08-31 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
CA2586365A1
(en)
*
|
2004-11-05 |
2006-05-26 |
Northwestern University |
Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
|
CA2588594C
(en)
|
2004-12-13 |
2014-02-18 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
US7385028B2
(en)
|
2004-12-22 |
2008-06-10 |
Ambrx, Inc |
Derivatization of non-natural amino acids and polypeptides
|
CA2590462C
(en)
|
2004-12-22 |
2017-02-28 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
CA2594557C
(en)
|
2004-12-22 |
2016-04-26 |
Ambrx, Inc. |
Modified human growth hormone
|
EP1674113A1
(en)
|
2004-12-22 |
2006-06-28 |
F. Hoffmann-La Roche Ag |
Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
|
CN102719366B
(zh)
*
|
2004-12-22 |
2014-07-16 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
CA2594561C
(en)
|
2004-12-22 |
2014-12-23 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
EP2514757A3
(en)
|
2005-01-10 |
2014-03-05 |
ratiopharm GmbH |
Glycopegylated granulocyte colony stimulating factor
|
KR101608083B1
(ko)
|
2005-01-25 |
2016-04-01 |
씨티아이 바이오파마 코포레이션 |
생체내 반감기가 변경된, 생물학적 활성을 갖는 단백질의접합체
|
AU2005326226B2
(en)
*
|
2005-01-31 |
2010-11-11 |
Eci, Inc. |
Immunopotentiating agent
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
SG159551A1
(en)
|
2005-02-11 |
2010-03-30 |
Amylin Pharmaceuticals Inc |
Gip analog and hybrid polypeptides with selectable properties
|
WO2006094530A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
WO2007010552A2
(en)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
N- terminal peg conjugate of erythropoietin
|
US7671023B2
(en)
|
2005-03-31 |
2010-03-02 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist for treating depression, anxiety disorder and schizophrenia
|
JP2008534640A
(ja)
|
2005-04-05 |
2008-08-28 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
タンパク質の機能部位またはエピトープの遮蔽方法
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
ES2538357T3
(es)
|
2005-04-11 |
2015-06-19 |
Crealta Pharmaceuticals Llc |
Formas variantes de urato oxidasa y uso de las mismas
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
MX2007014524A
(es)
|
2005-05-18 |
2008-02-07 |
Maxygen Inc |
Polipeptidos desarrollados de interferon-alfa.
|
EP1891231A4
(en)
|
2005-05-25 |
2011-06-22 |
Novo Nordisk As |
GLYCOPEGYLATED FACTOR IX
|
MX2007015156A
(es)
*
|
2005-06-01 |
2008-02-15 |
Maxygen Holdings Ltd |
Polipeptidos g-csf pegilados y metodos para la produccion de los mismos.
|
US20060286657A1
(en)
*
|
2005-06-01 |
2006-12-21 |
Samuel Zalipsky |
Novel bioconjugation reactions for acylating polyethylene glycol reagents
|
WO2007009208A1
(en)
*
|
2005-06-02 |
2007-01-25 |
Cangene Corporation |
Poly(ethylene glocol) modified human gm-csf with increased biological activity
|
EP1893229B1
(en)
*
|
2005-06-03 |
2011-10-19 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
CA2611836A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Nastech Pharmaceutical Company Inc. |
Transmucosal delivery of peptide derivatives
|
ES2553160T3
(es)
|
2005-06-17 |
2015-12-04 |
Novo Nordisk Health Care Ag |
Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
|
CN101242842A
(zh)
|
2005-06-17 |
2008-08-13 |
诺瓦提斯公司 |
Sanglifehrin在hcv中的用途
|
US7662370B2
(en)
*
|
2005-06-20 |
2010-02-16 |
Pepgen Corporation |
Low-toxicity, long-circulating human interferon-alpha PEGylated mutants
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
EP1926768B1
(en)
|
2005-07-18 |
2011-09-14 |
Nektar Therapeutics |
Branched functionalized polymers using branched polyol cores
|
KR100735784B1
(ko)
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
EA015752B1
(ru)
|
2005-07-25 |
2011-12-30 |
Интермьюн, Инк. |
Новые макроциклические ингибиторы репликации вируса гепатита с
|
CN101208386B
(zh)
*
|
2005-08-02 |
2012-07-18 |
第一毛织株式会社 |
一种用于封装半导体设备的环氧树脂组合物
|
CA2617064A1
(en)
*
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics Al, Corporation |
Conjugates of a g-csf moiety and a polymer
|
EP1922336B1
(en)
*
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
AU2005335491B2
(en)
|
2005-08-18 |
2010-11-25 |
Ambrx, Inc. |
Compositions of tRNA and uses thereof
|
EP1971362B1
(en)
|
2005-08-19 |
2014-12-03 |
Amylin Pharmaceuticals, LLC |
Exendin for treating diabetes and reducing body weight
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
EA200801050A1
(ru)
|
2005-10-11 |
2008-12-30 |
Интермьюн, Инк. |
Соединения и способы ингибирования репликации вирусного гепатита с
|
WO2007047303A2
(en)
*
|
2005-10-12 |
2007-04-26 |
Alvine Pharmaceuticals, Inc. |
Pegylated glutenase polypeptides
|
NZ568204A
(en)
|
2005-10-13 |
2012-01-12 |
Human Genome Sciences Inc |
Methods and compositions for use in treatment of patients with autoantibody positive diseases
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
JP2009514814A
(ja)
*
|
2005-10-21 |
2009-04-09 |
シナジェバ・バイオファーマ・コーポレイション |
グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
NZ567234A
(en)
*
|
2005-11-08 |
2011-09-30 |
Ambrx Inc |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
CN101454461A
(zh)
*
|
2005-11-16 |
2009-06-10 |
Ambrx公司 |
包括非天然氨基酸的方法和组合物
|
CN101448512B
(zh)
*
|
2005-12-14 |
2015-11-25 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
US8404643B2
(en)
|
2005-12-22 |
2013-03-26 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
RU2457854C2
(ru)
|
2005-12-30 |
2012-08-10 |
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед |
Длительное высвобождение нейрегулина для улучшения сердечной функции
|
EP1985303B1
(en)
|
2006-01-12 |
2012-11-21 |
Kitasato Daiichi Sankyo Vaccine Co., Ltd. |
Oral composition containing Interferon-alpha
|
CN100475270C
(zh)
*
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
EP1991577A2
(en)
|
2006-01-31 |
2008-11-19 |
Parkinson, John F. |
Modulation of mdl-1 activity for treatment of inflammatory disease
|
MX2008010841A
(es)
|
2006-02-21 |
2008-10-27 |
Nektar Therapeutics Al Corp |
Polimeros degradables segmentados y conjugados hechos de los mismos.
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
US20090306349A1
(en)
*
|
2006-03-31 |
2009-12-10 |
Rampak Corp |
Binding partners with immunoglobulin domains modified to have extended half-life
|
US7825152B2
(en)
|
2006-04-11 |
2010-11-02 |
Novartis Ag |
Organic compounds and their uses
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
WO2007133778A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
AU2007254141B2
(en)
|
2006-05-19 |
2012-10-11 |
Glycofi, Inc. |
Erythropoietin compositions
|
US20090252720A1
(en)
|
2006-05-24 |
2009-10-08 |
Novo Nordisk Health Care Ag |
Prolonged FIX Analogues and Derivatives
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
JP2009541333A
(ja)
*
|
2006-06-23 |
2009-11-26 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
修飾リボヌクレアーゼ
|
US20080096900A1
(en)
|
2006-06-26 |
2008-04-24 |
Amgen Inc. |
Methods for treating atherosclerosis
|
US8298801B2
(en)
*
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
ATE467642T1
(de)
*
|
2006-07-25 |
2010-05-15 |
Lipoxen Technologies Ltd |
Derivatisierung des granulozytenkoloniestimulierenden faktors
|
GB0615067D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Ttp Communications Ltd |
Reconfigurable signal processing scheme
|
KR20090046923A
(ko)
*
|
2006-08-04 |
2009-05-11 |
프로롱 파마슈티컬스, 인크. |
수식된 에리스로포이에틴
|
ITMI20061624A1
(it)
*
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
Mono-coniugati sito-specifici di g-csf
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
CL2007002502A1
(es)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
|
CA2658736C
(en)
*
|
2006-08-31 |
2014-08-12 |
F. Hoffman-La Roche Ag |
Method for the production of insulin-like growth factor-i
|
MX2009002523A
(es)
*
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Polipeptido de plasma humano modificado o andamios fc y sus usos.
|
CA2662753C
(en)
*
|
2006-09-08 |
2016-02-23 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
ES2465473T3
(es)
*
|
2006-09-08 |
2014-06-05 |
Ambrx, Inc. |
Transcripción de arnt supresor en células de vertebrado
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
MX2009003362A
(es)
|
2006-09-28 |
2009-06-08 |
Schering Corp |
Uso de interleucina-10 pegilada para tratamiento de cancer.
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
MX2009003470A
(es)
*
|
2006-10-04 |
2009-04-14 |
Novo Nordisk As |
Azucares y glicopeptidos pegilados enlazados a glicerol.
|
US20090252703A1
(en)
*
|
2006-10-19 |
2009-10-08 |
Gegg Jr Colin V |
Use of alcohol co-solvents to improve pegylation reaction yields
|
JO3048B1
(ar)
|
2006-10-25 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مشتقات متاستين واستخدامها
|
US7910102B2
(en)
|
2006-10-25 |
2011-03-22 |
Amgen Inc. |
Methods of using conjugated toxin peptide therapeutic agents
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
US7935796B2
(en)
|
2006-12-08 |
2011-05-03 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against ANGPTL3
|
WO2008097497A2
(en)
|
2007-02-02 |
2008-08-14 |
Adnexus, A Bristol-Myers Squibb R & D Company |
Vegf pathway blockade
|
CN101245109B
(zh)
*
|
2007-02-12 |
2011-12-14 |
杭州九源基因工程有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
|
MX2009010531A
(es)
|
2007-03-30 |
2009-11-26 |
Ambrx Inc |
Polipeptidos de fgf-21 modificados y usos de los mismos.
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
JP2008266219A
(ja)
*
|
2007-04-20 |
2008-11-06 |
National Institute Of Advanced Industrial & Technology |
リジン及びシステイン残基を含まないタンパク質
|
AU2008247637B2
(en)
|
2007-05-01 |
2013-12-05 |
Biogen Ma Inc. |
Compositions and methods for increasing vascularization
|
EP2076533B1
(en)
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CA2840407A1
(en)
|
2007-05-22 |
2008-12-18 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
JP2010531135A
(ja)
*
|
2007-06-04 |
2010-09-24 |
ノボ ノルディスク アクティーゼルスカブ |
N−アセチルグルコサミニルトランスフェラーゼを使用したo結合型グリコシル化
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
WO2009003188A2
(en)
*
|
2007-06-27 |
2008-12-31 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
PT2181190E
(pt)
|
2007-07-26 |
2014-02-24 |
Amgen Inc |
Enzimas aciltransferase de lecitina-colesterol modificadas
|
CN101352573B
(zh)
*
|
2007-07-27 |
2011-02-09 |
杭州九源基因工程有限公司 |
聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
|
WO2009023566A2
(en)
|
2007-08-09 |
2009-02-19 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
EP2578235A3
(en)
|
2007-08-27 |
2013-08-28 |
BioGeneriX AG |
Liquid formulation of G-CSF conjugate
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
WO2009046015A2
(en)
*
|
2007-09-30 |
2009-04-09 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
WO2009048909A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
CN101835496B
(zh)
|
2007-10-23 |
2015-11-25 |
尼克塔治疗公司 |
靶向羟基磷灰石的多臂聚合物以及由其制造的偶联物
|
WO2009067636A2
(en)
*
|
2007-11-20 |
2009-05-28 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
CA2707979A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Biovectra Inc. |
Polypeptides modified by protein trans-splicing technology
|
JP5806816B2
(ja)
|
2007-12-27 |
2015-11-10 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
生理学的に許容されるポリマー分子を特異的に検出するための方法および組成物
|
US20100316702A1
(en)
*
|
2008-01-08 |
2010-12-16 |
The Regents Of The University Of California |
Compositions and methods for regulating erythropoeitin expression and ameliorating anemia and stimulating erythropoiesis
|
CN102037004A
(zh)
*
|
2008-01-08 |
2011-04-27 |
生物种属学股份公司 |
使用寡糖基转移酶的多肽的糖缀合
|
EP3219795B1
(en)
|
2008-01-18 |
2024-03-13 |
BioMarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
NZ586947A
(en)
|
2008-02-08 |
2012-11-30 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
WO2009103199A1
(zh)
|
2008-02-18 |
2009-08-27 |
江苏恒瑞医药股份有限公司 |
水溶性聚合物修饰的g-csf偶联物
|
WO2009108806A1
(en)
|
2008-02-27 |
2009-09-03 |
Novo Nordisk A/S |
Conjugated factor viii molecules
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
RU2488598C2
(ru)
|
2008-04-03 |
2013-07-27 |
Биостид Джене Експрешен Тек. Ко., Лтд. |
Гормон роста, модифицированный двухцепочечным полиэтиленгликолем, способ его получения и применение
|
ATE533060T1
(de)
*
|
2008-04-03 |
2011-11-15 |
Hoffmann La Roche |
Assays mit pegylierten insulinähnlichen wachstumsfaktoren
|
WO2009128917A2
(en)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
US20110263496A1
(en)
|
2008-05-21 |
2011-10-27 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholesterol and triglycerides
|
EP2799448A1
(en)
|
2008-05-22 |
2014-11-05 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
EP2307456B1
(en)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
EP2318029B1
(en)
|
2008-07-23 |
2017-11-01 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
ES2617657T3
(es)
*
|
2008-07-30 |
2017-06-19 |
Takeda Pharmaceutical Company Limited |
Derivado de metastina y uso del mismo
|
WO2010014874A2
(en)
*
|
2008-07-31 |
2010-02-04 |
Pharmaessentia Corp. |
Peptide-polymer conjugates
|
CN102159250B
(zh)
|
2008-08-11 |
2014-08-06 |
尼克塔治疗公司 |
多臂的聚合烷酸酯偶联物
|
US8492503B2
(en)
|
2008-09-11 |
2013-07-23 |
Nektar Therapeutics |
Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
|
CA2738033C
(en)
|
2008-09-26 |
2019-11-26 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
ES2631915T3
(es)
|
2008-09-26 |
2017-09-06 |
Ambrx, Inc. |
Polipéptidos modificados de eritropoyetina animal y sus usos
|
CN102227443B
(zh)
|
2008-10-01 |
2014-05-14 |
昆特森斯生物科学公司 |
治疗性核糖核酸酶
|
SG195542A1
(en)
|
2008-10-10 |
2013-12-30 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
WO2010045321A2
(en)
|
2008-10-15 |
2010-04-22 |
Baxter International Inc. |
Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
|
JP5785872B2
(ja)
*
|
2008-10-17 |
2015-09-30 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
低度の水溶性ポリマーを含む改変血液因子
|
MX2011004195A
(es)
*
|
2008-10-20 |
2011-09-27 |
Usv Ltd |
Un proceso mejorado para la pegilacion de proteinas.
|
EP2431741B1
(en)
|
2008-10-21 |
2013-08-21 |
Baxter International Inc |
Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)
|
EP2344527A4
(en)
*
|
2008-10-31 |
2012-04-04 |
Amgen Inc |
MATERIALS AND METHODS FOR STEM CELL MOBILIZATION THROUGH A MULTIPLE PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR
|
IT1392655B1
(it)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
Site-specific monoconjugated insulinotropic glp-1 peptides.
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
JP5670913B2
(ja)
|
2008-12-09 |
2015-02-18 |
ハロザイム インコーポレイテッド |
延長された可溶性ph20ポリペプチドおよびその使用
|
AU2009324447B2
(en)
*
|
2008-12-11 |
2016-02-25 |
Takeda Pharmaceutical Company Limited |
Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
|
CA2745443C
(en)
|
2008-12-17 |
2017-02-21 |
Schering Corporation |
Mono- and di-peg il-10 production; and uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
WO2010129600A2
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
NZ596037A
(en)
|
2009-05-05 |
2013-10-25 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
DK3175863T3
(da)
|
2009-05-20 |
2022-02-07 |
Biomarin Pharm Inc |
Varianter af c-type natriuretisk peptid
|
CA2764835A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
EP2442824A2
(en)
|
2009-06-19 |
2012-04-25 |
MedImmune, LLC |
Protease variants
|
SG176897A1
(en)
|
2009-06-25 |
2012-01-30 |
Savient Pharmaceuticals Inc |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
DK2477603T3
(en)
|
2009-09-17 |
2016-06-13 |
Baxalta Inc |
STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
|
JP5885664B2
(ja)
|
2009-09-25 |
2016-03-15 |
ゾーマ テクノロジー リミテッド |
スクリーニング法
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011037896A2
(en)
*
|
2009-09-25 |
2011-03-31 |
Vybion, Inc. |
Polypeptide modification
|
US9315860B2
(en)
|
2009-10-26 |
2016-04-19 |
Genovoxx Gmbh |
Conjugates of nucleotides and method for the application thereof
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
CA2778678A1
(en)
|
2009-10-30 |
2011-05-05 |
Cns Therapeutics, Inc. |
Improved neurturin molecules
|
KR20120116942A
(ko)
|
2009-11-23 |
2012-10-23 |
아밀린 파마슈티칼스, 인크. |
폴리펩티드 접합체
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
AU2010341518B2
(en)
|
2009-12-21 |
2014-01-09 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
US20110152188A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Hanns-Christian Mahler |
Pharmaceutical compositions of igf/i proteins
|
US20130040888A1
(en)
|
2010-02-16 |
2013-02-14 |
Novo Nordisk A/S |
Factor VIII Molecules With Reduced VWF Binding
|
ES2639398T3
(es)
|
2010-03-04 |
2017-10-26 |
Pfenex Inc. |
Método para producir proteína de interferón recombinante soluble sin desnaturalización
|
AU2011235210B2
(en)
|
2010-04-01 |
2015-07-16 |
Pfenex Inc. |
Methods for G-CSF production in a Pseudomonas host cell
|
MX2012011986A
(es)
|
2010-04-15 |
2013-03-05 |
Amgen Inc |
RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
|
CA2797093C
(en)
|
2010-04-26 |
2019-10-29 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
US8961960B2
(en)
|
2010-04-27 |
2015-02-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
AU2011248490B2
(en)
|
2010-04-29 |
2016-11-10 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
|
WO2011139907A2
(en)
|
2010-04-29 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
CN102234310B
(zh)
*
|
2010-04-30 |
2017-02-08 |
杭州九源基因工程有限公司 |
一种聚乙二醇修饰蛋白的分离纯化方法
|
WO2011140135A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
EP2566495B1
(en)
|
2010-05-03 |
2017-03-01 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
|
AU2011248355B2
(en)
|
2010-05-03 |
2017-01-19 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
|
EP2566499B1
(en)
|
2010-05-04 |
2017-01-25 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
AU2011252990B2
(en)
|
2010-05-14 |
2017-04-20 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
US9034598B2
(en)
|
2010-05-17 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
|
EP2571896A4
(en)
|
2010-05-17 |
2014-01-08 |
Cebix Inc |
PEGYLATED C-PEPTIDE
|
US9562089B2
(en)
|
2010-05-26 |
2017-02-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
JP6046607B2
(ja)
|
2010-05-27 |
2016-12-21 |
エータイアー ファーマ, インコーポレイテッド |
グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CN103118694B
(zh)
|
2010-06-01 |
2016-08-03 |
Atyr医药公司 |
与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
CN102711871A
(zh)
|
2010-06-16 |
2012-10-03 |
麦德托尼克公司 |
用于稳定药物递送装置中的药物的阻尼系统
|
CA2803093A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
CA2804416C
(en)
|
2010-07-12 |
2020-04-28 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
JP2013532176A
(ja)
|
2010-07-15 |
2013-08-15 |
ノヴォ ノルディスク アー/エス |
安定化させた第viii因子バリアント
|
MX348420B
(es)
|
2010-07-20 |
2017-06-12 |
Halozyme Inc |
Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
|
AR082319A1
(es)
|
2010-07-22 |
2012-11-28 |
Biomarin Pharm Inc |
Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
RU2446173C1
(ru)
*
|
2010-08-13 |
2012-03-27 |
Зао "Биокад" |
Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
HRP20240267T1
(hr)
|
2010-08-17 |
2024-05-10 |
Ambrx, Inc. |
Modificirani relaksin polipeptidi i njihove uporabe
|
CA2808539C
(en)
|
2010-08-25 |
2021-05-25 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
|
WO2012035050A2
(en)
|
2010-09-15 |
2012-03-22 |
Novo Nordisk A/S |
Factor viii variants having a decreased cellular uptake
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
BR112013007385B1
(pt)
|
2010-09-28 |
2022-07-26 |
Amylin Pharmaceuticals, Llc |
Polipeptídeo quimérico, seu uso e composição que o compreende
|
MX2013003903A
(es)
|
2010-10-05 |
2013-05-20 |
Novartis Ag |
Nuevos tratamientos de infeccion por el virus de hepatitis c.
|
KR20130120481A
(ko)
|
2010-10-08 |
2013-11-04 |
노파르티스 아게 |
술파미드 ns3 억제제의 비타민 e 제제
|
CN102453089B
(zh)
*
|
2010-10-25 |
2014-06-04 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
CN103933577B
(zh)
*
|
2010-10-25 |
2014-12-10 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
CA2817415C
(en)
|
2010-11-24 |
2020-05-12 |
Lexicon Pharmaceuticals, Inc. |
Antibodies that bind notum pectinacetylesterase
|
BR112013013166A2
(pt)
|
2010-11-30 |
2016-09-06 |
Novartis Ag |
tratamentos da infecção pelo vírus da hepatite c
|
CN102485742A
(zh)
*
|
2010-12-02 |
2012-06-06 |
山东新时代药业有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
|
WO2012083197A1
(en)
|
2010-12-17 |
2012-06-21 |
Nektar Therapeutics |
Water-soluble polymer conjugates of topotecan
|
WO2012088282A1
(en)
|
2010-12-21 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
|
WO2012088445A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
WO2012088422A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
EP2907504B1
(en)
|
2011-02-08 |
2017-06-28 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
UY33959A
(es)
|
2011-03-16 |
2012-09-28 |
Amgen Inc |
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7
|
US20140171365A1
(en)
*
|
2011-03-25 |
2014-06-19 |
The Trustees Of Columbia University In The City Of New York |
Pegylated human hdl particle and process for production thereof
|
US20140018289A1
(en)
|
2011-03-31 |
2014-01-16 |
Novartis Ag |
New treatments of Hepatitis C virus infection
|
RS53911B1
(en)
|
2011-04-01 |
2015-08-31 |
Novartis Ag |
TREATMENT IN HEPATITIS B VIRUS INFECTION ONLY OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND THE DISEASES OF THE LIVER
|
BR112013025934A2
(pt)
|
2011-04-13 |
2016-09-06 |
Debiopharm Int Sa |
tratamento de infecção pelo vírus da hepatite c com alisporivir
|
EP2709669A1
(en)
|
2011-05-17 |
2014-03-26 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
DK2714735T3
(da)
|
2011-06-03 |
2021-10-18 |
Xoma Technology Ltd |
Antistoffer, der er specifikke for TGF-beta
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
KR101676543B1
(ko)
|
2011-06-17 |
2016-11-15 |
할로자임, 아이엔씨 |
히알루로난 분해효소를 이용한 연속적인 피하 인슐린 주입 방법
|
US20130090294A1
(en)
|
2011-06-28 |
2013-04-11 |
Alternative Innovative Technologies Llc |
Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
|
CA2840552A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
HUE029855T2
(en)
|
2011-07-05 |
2017-04-28 |
Bioasis Technologies Inc |
p97 antibody conjugates
|
WO2013009539A1
(en)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action and reduced immunogenicity
|
CN102952067A
(zh)
*
|
2011-08-30 |
2013-03-06 |
苏州欣诺科生物科技有限公司 |
用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用
|
WO2013033452A2
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
JP2014528947A
(ja)
|
2011-09-27 |
2014-10-30 |
ノバルティス アーゲー |
C型肝炎ウイルス感染症の治療のためのアリスポリビル
|
WO2013056197A1
(en)
|
2011-10-14 |
2013-04-18 |
Alternative Innovative Technologies Llc |
Degradation resistant hsp70 formulations and uses thereof
|
US8846034B2
(en)
|
2011-10-24 |
2014-09-30 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
WO2013063283A1
(en)
|
2011-10-25 |
2013-05-02 |
Corning Incorporated |
Delamination resistant pharmaceuticals glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
EP2773659A2
(en)
|
2011-10-31 |
2014-09-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
US8962553B2
(en)
|
2011-11-17 |
2015-02-24 |
Cebix Ab |
Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
|
WO2013101509A2
(en)
|
2011-12-15 |
2013-07-04 |
Alternative Innovative Technologies Llc |
Hsp70 fusion protein conjugates and uses thereof
|
CA2861919C
(en)
|
2011-12-30 |
2019-04-02 |
Halozyme, Inc. |
Ph20 polypeptide variants, formulations and uses thereof
|
DK2809350T3
(en)
|
2012-01-30 |
2019-01-28 |
Arecor Ltd |
STABILIZED Aqueous Antibody Preparations
|
EP2814514B1
(en)
|
2012-02-16 |
2017-09-13 |
Atyr Pharma, Inc. |
Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
|
AU2013226090B2
(en)
|
2012-02-27 |
2018-03-08 |
Amunix Operating Inc. |
XTEN conjugate compositions and methods of making same
|
CA2865879A1
(en)
|
2012-02-29 |
2013-09-06 |
Toray Industries, Inc. |
Inhibitory agent for body cavity fluid accumulation
|
IN2014DN08236A
(nl)
|
2012-03-03 |
2015-05-15 |
Immungene Inc |
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
WO2013149219A2
(en)
|
2012-03-30 |
2013-10-03 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
SI2833905T1
(en)
|
2012-04-04 |
2018-08-31 |
Halozyme, Inc. |
Combination therapy with hyaluronidase and tumane-directed taxane
|
KR102284247B1
(ko)
|
2012-05-31 |
2021-08-03 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
CN105051065A
(zh)
|
2012-06-22 |
2015-11-11 |
索伦托治疗有限公司 |
与ccr2结合的抗原结合蛋白
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
AU2013296557B2
(en)
|
2012-07-31 |
2019-04-18 |
Bioasis Technologies Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
EP2890402B1
(en)
|
2012-08-31 |
2019-04-17 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
JP2016500058A
(ja)
|
2012-11-12 |
2016-01-07 |
レッドウッド バイオサイエンス, インコーポレイテッド |
化合物および抱合体を生成するための方法
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
US9605078B2
(en)
|
2012-11-16 |
2017-03-28 |
The Regents Of The University Of California |
Pictet-Spengler ligation for protein chemical modification
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
US20160067347A1
(en)
|
2012-12-20 |
2016-03-10 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
CN103908660B
(zh)
*
|
2013-01-05 |
2015-02-04 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法
|
WO2014120891A2
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
CN103113466B
(zh)
*
|
2013-03-01 |
2015-06-03 |
中国科学院过程工程研究所 |
聚乙二醇修饰的重组人干扰素β-1b及制备方法
|
TW201446792A
(zh)
|
2013-03-12 |
2014-12-16 |
Amgen Inc |
Nav1.7之強效及選擇性抑制劑
|
CA2906003C
(en)
|
2013-03-13 |
2021-07-06 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
RU2535002C2
(ru)
*
|
2013-04-04 |
2014-12-10 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук |
Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
|
BR112015026122A8
(pt)
|
2013-04-18 |
2020-01-21 |
Armo Biosciences Inc |
agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9823255B2
(en)
|
2013-06-17 |
2017-11-21 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
JP6509867B2
(ja)
|
2013-08-30 |
2019-05-08 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を治療するためにインターロイキン−10を使用する方法
|
BR112016005716A2
(pt)
|
2013-10-02 |
2017-09-12 |
Nat Institutes Of Health |
miméticos de fator de crescimento semelhante à insulina para uso em terapia
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
RU2016122957A
(ru)
|
2013-11-11 |
2017-12-19 |
Армо Байосайенсиз, Инк. |
Способы применения интерлейкина-10 для лечения заболеваний и расстройств
|
EP3068891A1
(en)
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Engineered glycoproteins and uses thereof
|
US9493413B2
(en)
|
2013-11-27 |
2016-11-15 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
UY35874A
(es)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
Un proceso para la preparación de una composición de proteínas pegiladas
|
WO2015130963A2
(en)
|
2014-02-27 |
2015-09-03 |
Xenetic Biosciences, Inc. |
Compositions and methods for administering insulin or insulin-like protein to the brain
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
CA2951391C
(en)
|
2014-06-10 |
2021-11-02 |
Amgen Inc. |
Apelin polypeptides
|
HRP20211561T8
(hr)
|
2014-06-12 |
2022-03-04 |
Ra Pharmaceuticals, Inc. |
Modulacija aktivnosti komplementa
|
SG11201701382PA
(en)
|
2014-08-22 |
2017-03-30 |
Sorrento Therapeutics Inc |
Antigen binding proteins that bind cxcr3
|
ES2727137T3
(es)
|
2014-08-28 |
2019-10-14 |
Halozyme Inc |
Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
|
EP3206713A4
(en)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
WO2016061286A2
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
KR20170084033A
(ko)
|
2014-10-22 |
2017-07-19 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
|
WO2016065326A2
(en)
|
2014-10-24 |
2016-04-28 |
Bristol-Myers Squibb Company |
Modified fgf-21 polypeptides and uses thereof
|
HUE064909T2
(hu)
|
2014-11-06 |
2024-04-28 |
Pharmaessentia Corp |
Adagolási rendszer pegilált interferonhoz
|
US20160151511A1
(en)
*
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
CN104491843B
(zh)
*
|
2015-01-23 |
2017-09-12 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG‑CSF活性药物组合物
|
WO2016123371A1
(en)
|
2015-01-28 |
2016-08-04 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
TWI708611B
(zh)
*
|
2015-03-03 |
2020-11-01 |
香港商南沙生物科技(香港)有限公司 |
聚乙二醇化介白素-11之組合物及方法
|
JP6901400B2
(ja)
|
2015-04-03 |
2021-07-14 |
ゾーマ テクノロジー リミテッド |
TGF−β及びPD−1の阻害物質を使用する癌の治療法
|
WO2016167291A1
(ja)
|
2015-04-13 |
2016-10-20 |
国立研究開発法人産業技術総合研究所 |
環状化サイトカイン及びその製法
|
CA2981822C
(en)
|
2015-05-01 |
2023-04-11 |
Allysta Pharmaceuticals, Inc. |
Adiponectin peptidomimetics for treating ocular disorders
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
AU2016304588A1
(en)
|
2015-08-06 |
2018-02-15 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
WO2017035232A1
(en)
|
2015-08-25 |
2017-03-02 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EP3351561A4
(en)
*
|
2015-09-18 |
2019-05-15 |
University of Miyazaki |
PROLONGED ACTION ADRENOMEDULLIN DERIVATIVE
|
JP2018529729A
(ja)
|
2015-10-01 |
2018-10-11 |
アムジエン・インコーポレーテツド |
胆汁酸障害の処置
|
US10935276B2
(en)
|
2015-10-20 |
2021-03-02 |
Steven Michalski |
Air mixing device
|
DK3373937T3
(da)
|
2015-11-09 |
2022-03-14 |
Scherer Technologies Llc R P |
Anti-cd22-antistof-maytansin-konjugater og fremgangsmåder til anvendelse deraf
|
PT3386531T
(pt)
|
2015-12-08 |
2021-12-29 |
Biomarin Pharm Inc |
Uso de variantes do péptido natriurético tipo c para tratar a osteoartrite
|
SG11201804721SA
(en)
|
2015-12-16 |
2018-07-30 |
Ra Pharmaceuticals Inc |
Modulators of complement activity
|
JP6883590B2
(ja)
|
2016-01-29 |
2021-06-09 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Pd−l1に結合する抗原結合性タンパク質
|
WO2018026748A1
(en)
|
2016-08-01 |
2018-02-08 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
|
CN110087681A
(zh)
|
2016-09-28 |
2019-08-02 |
佐马美国有限公司 |
结合白细胞介素-2的抗体和其用途
|
BR112019011053A2
(pt)
|
2016-12-07 |
2019-10-15 |
Ra Pharmaceuticals Inc |
moduladores da atividade do complemento
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
KR102670432B1
(ko)
|
2017-02-08 |
2024-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
|
IL271587B2
(en)
|
2017-06-22 |
2024-05-01 |
Catalyst Biosciences Inc |
Modified membrane-type serine protease 1 polypeptides (MTSP-1) and methods of use
|
KR102020995B1
(ko)
|
2017-10-30 |
2019-09-16 |
한국코러스 주식회사 |
콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
|
CN111094462A
(zh)
|
2017-12-26 |
2020-05-01 |
贝克顿·迪金森公司 |
深紫外线可激发的水溶剂化聚合物染料
|
WO2019130344A1
(en)
|
2017-12-27 |
2019-07-04 |
Council Of Scientific And Industrial Research |
A polypeptide exhibiting granulocyte-colony stimulating factor activity
|
EP3765484A4
(en)
*
|
2018-03-14 |
2021-12-22 |
Ba, Yong |
PEGYLATED ANTIFREEZE PROTEINS AND PROCESSES FOR PREPARATION AND USE
|
EP3775052B1
(en)
|
2018-03-30 |
2024-06-05 |
Becton, Dickinson and Company |
Water-soluble polymeric dyes having pendant chromophores
|
CA3097968A1
(en)
|
2018-04-24 |
2019-10-31 |
Andrew Phillip SPASOFF |
Method for making injectable pharmaceutical compositions
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
WO2020023300A1
(en)
|
2018-07-22 |
2020-01-30 |
Bioasis Technologies, Inc. |
Treatment of lymmphatic metastases
|
HUE065882T2
(hu)
|
2018-09-11 |
2024-06-28 |
Ambrx Inc |
Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
AU2019413431A1
(en)
|
2018-12-28 |
2021-07-08 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
US10882954B2
(en)
|
2019-04-11 |
2021-01-05 |
Sunbio Inc. |
Tertiary alkoxy polyethylene glycol and derivatives thereof
|
US20220185969A1
(en)
*
|
2019-04-15 |
2022-06-16 |
Nof Corporation |
Conjugate of bio-related substance and block polymer, and block polymer derivative for obtaining said conjugate
|
AU2020258384A1
(en)
|
2019-04-15 |
2021-11-04 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
|
CN115243726A
(zh)
|
2020-03-11 |
2022-10-25 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其使用方法
|
US20230204597A1
(en)
|
2020-03-20 |
2023-06-29 |
Amgen Inc. |
Determination of free n-terminus of pegfilgrastim using an acid protease
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
US11602598B1
(en)
*
|
2020-08-27 |
2023-03-14 |
Fresenius Kabi Deutschland Gmbh |
Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
|
CN112710826A
(zh)
*
|
2020-11-17 |
2021-04-27 |
北京九强生物技术股份有限公司 |
一种提高试剂稳定性的包被和封闭方法
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
MX2023011480A
(es)
|
2021-04-03 |
2023-12-06 |
Ambrx Inc |
Conjugados anticuerpo anti-her2-fármaco y usos de estos.
|
CN113214328B
(zh)
*
|
2021-05-08 |
2022-06-28 |
宁波经济技术开发区弘翔生化科技有限公司 |
一种双水相体系以及基于双水相体系的单糖分离方法
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|
WO2024196805A1
(en)
|
2023-03-17 |
2024-09-26 |
Beckman Coulter, Inc. |
Benzothienopyrrole cyanine dyes
|